Combination treatment for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a combination of two new investigational drugs for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drugs aim to help your immune system fight the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer that has spread to other parts of the body and is still growing despite hormone therapy (castration-resistant).
- Your PSA level must be 2 or higher.
- You must have had treatment to lower testosterone or have had your testicles removed.
- You must not have certain types of prostate cancer, like small cell or neuroendocrine cancer (unless it's a mixed type).
- You must not have brain metastases unless they are treated, stable, and you've been off steroids for more than 2 weeks.
- You must not have taken certain anti-cancer drugs within the recent past (e.g., immunotherapy within 6 weeks, certain targeted therapy within 3 months, other drugs within 14 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called JNJ-98768111 in people with advanced prostate cancer that has spread and is no longer responding to current hormone-based treatments. It aims to see if the drug is safe and effective, and participants will receive the study drug while continuing some standard hormone therapy.
This trial tests a new combination of two drugs, pasritamig and JNJ-86974680, for men with a certain type of advanced prostate cancer that has spread to bone or lymph nodes but not to organs like the lungs or liver. It aims to see if this combination is safe and effective.
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
This study tests a combination of two drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs are cabozantinib (a pill that may slow cancer growth) and a radioactive therapy that targets prostate cancer cells (177Lu-PSMA-617). The goal is to see if this combination is safe and effective.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This trial tests an experimental new drug (GSK5471713) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It is for people who have already tried certain hormone treatments and chemotherapy.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.